JAMJOOM PHARMA
4015TASIPharmaBiotech & Life Science
125.40SAR(2.60) (2.03%)
- Open
- 128.00
- High
- 128.00
- Low
- 125.40
- Prev. close
- 128.00
- Volume
- 28.80K
- Value
- 3.63M
- Trades
- 711
4015TASIPharmaBiotech & Life Science
Coming soon
We are confirming a reliable source for this data and its terms of use before adding it.
Coming soon
We are confirming a reliable source for this data and its terms of use before adding it.
No private deals recorded for this company.
Jamjoom Pharmaceuticals Factory Company, together with its subsidiaries, engages in the manufacture and distribution of pharmaceutical and consumer products in the Kingdom of Saudi Arabia, Gulf, Iraq, Egypt, North Africa, and internationally. It provides human medicines; nutraceuticals; antibiotics; general analgesics; medicines for treatment of cough, allergy, asthma, heart diseases, blood pressure, diarrhea, vomiting, and ulcer and acidity; treatment of various skin infections and cancer diseases; and eye drops, and ointments and cosmeceuticals. The company also offers ophthalmic solutions, dermatology products, cardiovascular health, consumer health, respiratory health, gastrointestinal health, endocrinology and diabetes care, central nervous system, and pain and inflammation pharmaceutical products. Jamjoom Pharmaceuticals Factory Company was founded in 1994 and is based in Jeddah, the Kingdom of Saudi Arabia.
31 December 2026Regulatory actionImportant
جمجوم فارما تتوقع الحصول على الموافقات التنظيمية من الهيئة العامة للغذاء والدواء السعودية قبل نهاية 2026 لإطلاق أول منتج بدائل حيوية في 2027.
11 October 2026Financial results
توقعات جي آي بي كابيتال لأرباح جمجوم فارما للربع الثالث 2026 بانخفاض طفيف بنسبة 2.5% مقارنة بالعام السابق.
1 October 2026Product launchImportant
جمجوم فارما تتوقع الحصول على موافقات لإطلاق أول منتجين من البدائل الحيوية في السوق السعودي خلال الربع الرابع 2026 أو الربع الأول 2027.
1 October 2026Partnership & contractsImportant
جمجوم فارما تعلن توقيع اتفاقية شراكة استراتيجية مع شركة لايفيرا وتأسيس كيان جديد لتوطين تصنيع اللقاحات والأدوية الحيوية في أكتوبر 2026.
52-week range
| Eligibility | Distribution | Amount |
|---|---|---|
| 30 Jul 2026 | 13 Aug 2026 | 2.20 |
| 1 Mar 2026 | 15 Mar 2026 | 2.00 |
| 28 Jul 2025 | 10 Aug 2025 | 2.00 |
| 4 Mar 2025 | 17 Mar 2025 | 1.46 |
| 15 Aug 2024 | 25 Aug 2024 | 1.60 |
| Company | Price | Change % | Market cap | P/E | Net margin | Dividend yield |
|---|---|---|---|---|---|---|
| 125.40 | (2.03%) | 8.78B | 18.3 | 30.91% | 3.35% | |
| 29.76 | (2.30%) | 3.57B | 16.4 | 10.80% | 1.18% | |
| 63.35 | 0.16% | 2.22B | 20.4 | 21.07% | 3.35% |